ReviewFrontiers in molecular neuroscience2025
Peripheral-central immune interactions in Parkinson's disease: insights into innate and adaptive immunity.
Review in Frontiers in molecular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Astrocyte reactivity by alcohol dependence in the central amygdala.Brain, behavior, and immunity · 2026Article
- From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease.Materials today. Bio · 2026Article
- Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease.Inflammopharmacology · 2026Review
- Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.Brain, behavior, & immunity - health · 2026Article
- Astrocyte Reactivity by Alcohol Dependence in the Central Amygdala.bioRxiv : the preprint server for biology · 2026Article
- Pathogen Antibodies and Parkinson's Disease: A Two-sample Mendelian Randomization Study.Current neurovascular research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a complex, multisystem disorder characterized by chronic inflammatory processes. The development of effective immunomodulatory therapies for PD requires a novel and comprehensive understanding of the coordinated interactions between central and peripheral innate and adaptive immune responses that are initiated and evolve throughout disease onset and progression. Immune system dysregulation is a defining feature of PD, with a substantial body of evidence indicating pathological alterations in both central and peripheral immune responses that evolve dynamically over the course of the disease. In PD, central inflammation is defined by the activation of astrocytes, microglia and T-cell responses within the central nervous system. In contrast, peripheral inflammation involves the activation of T-cell signaling and innate immune cells in the enteric nervous system, circulatory system and gastrointestinal tract. However, the underlying mechanisms of this inflammation in PD-associated diseases remain unclear, and identifying the initial stages of these diseases is a major unmet need. This review seeks to address this question by highlighting and discussing the central and peripheral systems through the collection of current data from clinical evidence and findings from experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.